No Data
No Data
Buy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical Trials
Express News | Sellas Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Express News | Sellas Life Sciences Q2 Basic EPS USD -0.13
Express News | Sellas Life Sciences Q2 Operating Income USD -7.621 Million
Sellas Life Sciences | 10-Q: Q2 2024 Earnings Report
Express News | Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas
No Data